Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Abacus Medicine Pharma Services ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.1% 1.1%   Bankruptcy risk   0.9% 1.2% 1.7% 1.5% 1.9% 1.3% 7.4% 7.4%   Credit score (0-100)   90 83 73 74 69 78 33 33   Credit rating   A A A A A A BBB BBB   Credit limit (kDKK)   1,006.6 397.8 24.4 74.4 5.6 280.2 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   -61.8 -212 -63.5 -43.1 -36.3 -72.9 0.0 0.0   EBITDA   -61.8 -212 -63.5 -43.1 -49.5 -72.9 0.0 0.0   EBIT   -61.8 -212 -63.5 -43.1 -49.5 -72.9 0.0 0.0   Pre-tax profit (PTP)   1,105.1 701.6 241.4 3,562.5 -5,837.8 1,776.8 0.0 0.0   Net earnings   860.4 547.6 188.3 2,778.7 -4,553.5 1,385.5 0.0 0.0   Pre-tax profit without non-rec. items   1,105 702 241 3,562 -5,838 1,777 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   15,336 15,884 22,572 25,351 20,797 22,183 21,683 21,683   Interest-bearing liabilities   0.0 6,496 35,836 62,056 82,396 104,558 0.0 0.0   Balance sheet total (assets)   21,534 22,586 58,495 88,225 103,224 127,181 21,683 21,683   Net Debt   -73.4 6,486 35,836 62,054 82,222 104,558 -21,683 -21,683     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   -61.8 -212 -63.5 -43.1 -36.3 -72.9 0.0 0.0   Gross profit growth   0.0% -243.5% 70.1% 32.1% 15.8% -100.5% 0.0% 0.0%   Employees   0 0 0 0 0 0 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   21,534 22,586 58,495 88,225 103,224 127,181 21,683 21,683   Balance sheet change%   0.0% 4.9% 159.0% 50.8% 17.0% 23.2% -83.0% 0.0%   Added value   -61.8 -212.2 -63.5 -43.1 -49.5 -72.9 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -1.0 -2.0 -3.0 -4.0 -5.0 -5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   100.0% 100.0% 100.0% 100.0% 136.3% 100.0% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   6.5% 4.8% 2.0% 8.3% 4.1% 5.8% 0.0% 0.0%   ROI %   6.6% 4.8% 2.0% 8.4% 4.1% 5.8% 0.0% 0.0%   ROE %   5.6% 3.5% 1.0% 11.6% -19.7% 6.4% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   71.2% 70.3% 38.6% 28.7% 20.1% 17.4% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   118.9% -3,056.9% -56,452.9% -143,866.0% -165,964.0% -143,514.5% 0.0% 0.0%   Gearing %   0.0% 40.9% 158.8% 244.8% 396.2% 471.3% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 10.8% 2.7% 5.2% 13.5% 5.2% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   4.8 0.0 0.0 0.0 0.5 0.5 0.0 0.0   Current Ratio   4.8 0.0 0.0 0.0 0.5 0.5 0.0 0.0   Cash and cash equivalent   73.4 10.0 0.0 2.7 174.3 0.0 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   1,123.7 -6,509.8 -35,237.8 -60,939.0 -1,334.4 -1,924.5 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0